Literature DB >> 24271936

Natural history of Sanfilippo syndrome type A.

Dakota Buhrman1, Kavita Thakkar, Michele Poe, Maria L Escolar.   

Abstract

OBJECTIVE: To describe the natural history of Sanfilippo syndrome type A.
METHODS: We performed a retrospective review of 46 children (21 boys, 25 girls) with Sanfilippo syndrome type A evaluated between January 2000 and April 2013. Assessments included neurodevelopmental evaluations, audiologic testing, and assessment of growth, adaptive behavior, cognitive behavior, motor function, and speech/language skills. Only the baseline evaluation was included for patients who received hematopoietic stem cell transplantation.
RESULTS: Median age at diagnosis was 35 months, with a median delay between initial symptoms to diagnosis of 24 months. The most common initial symptoms were speech/language delay (48%), dysmorphology (22%), and hearing loss (20%). Early behavioral problems included perseverative chewing and difficulty with toilet training. All children developed sleep difficulties and behavioral changes (e.g., hyperactivity, aggression). More than 93% of the children experienced somatic symptoms such as hepatomegaly (67%), abnormal dentition (39%), enlarged tongue (37%), coarse facial features (76%), and protuberant abdomen (43%). Kaplan-Meier analysis showed a 60% probability of surviving past 17 years of age.
CONCLUSIONS: Sanfilippo type A is characterized by severe hearing loss and speech delay, followed by a rapid decline in cognitive skills by 3 years of age. Significant somatic disease occurs in more than half of patients. Behavioral difficulties presented between 2 and 4 years of age during a rapid period of cognitive decline. Gross motor abilities are maintained during this period, which results in an active child with impaired cognition. Sleep difficulties are concurrent with the period of cognitive degeneration. There is currently an unacceptable delay in diagnosis, highlighting the need to increase awareness of this disease among clinicians.

Entities:  

Mesh:

Year:  2013        PMID: 24271936     DOI: 10.1007/s10545-013-9661-8

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  17 in total

1.  Mucopolysaccharidosis type III (Sanfilippo disease) in Sweden: clinical presentation of 22 children diagnosed during a 30-year period.

Authors:  G Malm; J-E Månsson
Journal:  Acta Paediatr       Date:  2010-03-14       Impact factor: 2.299

Review 2.  Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications.

Authors:  G Yogalingam; J J Hopwood
Journal:  Hum Mutat       Date:  2001-10       Impact factor: 4.878

Review 3.  Management of mucopolysaccharidosis type III.

Authors:  M A Cleary; J E Wraith
Journal:  Arch Dis Child       Date:  1993-09       Impact factor: 3.791

4.  Enzyme replacement reduces neuropathology in MPS IIIA dogs.

Authors:  Allison C Crawley; Neil Marshall; Helen Beard; Sofia Hassiotis; Vicki Walsh; Barbara King; Nicola Hucker; Maria Fuller; Robert D Jolly; John J Hopwood; Kim M Hemsley
Journal:  Neurobiol Dis       Date:  2011-04-29       Impact factor: 5.996

5.  Hematopoietic stem cell and gene therapy corrects primary neuropathology and behavior in mucopolysaccharidosis IIIA mice.

Authors:  Alexander Langford-Smith; Fiona L Wilkinson; Kia J Langford-Smith; Rebecca J Holley; Ana Sergijenko; Steven J Howe; William R Bennett; Simon A Jones; Je Wraith; Catherine Lr Merry; Robert F Wynn; Brian W Bigger
Journal:  Mol Ther       Date:  2012-05-01       Impact factor: 11.454

6.  Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy.

Authors:  Virginia Haurigot; Sara Marcó; Albert Ribera; Miguel Garcia; Albert Ruzo; Pilar Villacampa; Eduard Ayuso; Sònia Añor; Anna Andaluz; Mercedes Pineda; Gemma García-Fructuoso; Maria Molas; Luca Maggioni; Sergio Muñoz; Sandra Motas; Jesús Ruberte; Federico Mingozzi; Martí Pumarola; Fatima Bosch
Journal:  J Clin Invest       Date:  2013-07-01       Impact factor: 14.808

7.  Genetic heterogeneity and clinical variability in the Sanfilippo syndrome (types A, B, and C).

Authors:  J J van de Kamp; M F Niermeijer; K von Figura; M A Giesberts
Journal:  Clin Genet       Date:  1981-08       Impact factor: 4.438

Review 8.  Methods for assessing neurodevelopment in lysosomal storage diseases and related disorders: a multidisciplinary perspective.

Authors:  Holly R Martin; Michele D Poe; Debra Reinhartsen; Rebecca E Pretzel; Jackson Roush; Angela Rosenberg; Stacey C Dusing; Maria L Escolar
Journal:  Acta Paediatr       Date:  2008-04       Impact factor: 2.299

9.  The mutation p.Ser298Pro in the sulphamidase gene (SGSH) is associated with a slowly progressive clinical phenotype in mucopolysaccharidosis type IIIA (Sanfilippo A syndrome).

Authors:  Ann Meyer; Kai Kossow; Andreas Gal; Cordula Steglich; Chris Mühlhausen; Kurt Ullrich; Thomas Braulke; Nicole Muschol
Journal:  Hum Mutat       Date:  2008-05       Impact factor: 4.878

10.  Two-year follow-up of Sanfilippo Disease patients treated with a genistein-rich isoflavone extract: assessment of effects on cognitive functions and general status of patients.

Authors:  Ewa Piotrowska; Joanna Jakobkiewicz-Banecka; Agnieszka Maryniak; Anna Tylki-Szymanska; Ewa Puk; Anna Liberek; Alicja Wegrzyn; Barbara Czartoryska; Monika Slominska-Wojewodzka; Grzegorz Wegrzyn
Journal:  Med Sci Monit       Date:  2011-04
View more
  23 in total

1.  A Prospective Natural History Study of Mucopolysaccharidosis Type IIIA.

Authors:  Elsa G Shapiro; Igor Nestrasil; Kathleen A Delaney; Kyle Rudser; Victor Kovac; Nitin Nair; Charles W Richard; Patrick Haslett; Chester B Whitley
Journal:  J Pediatr       Date:  2016-01-16       Impact factor: 4.406

2.  Early Umbilical Cord Blood-Derived Stem Cell Transplantation Does Not Prevent Neurological Deterioration in Mucopolysaccharidosis Type III.

Authors:  Lindsey Welling; Jan Pieter Marchal; Peter van Hasselt; Ans T van der Ploeg; Frits A Wijburg; Jaap Jan Boelens
Journal:  JIMD Rep       Date:  2014-09-26

Review 3.  Associations and Disease-Disease Interactions of COVID-19 with Congenital and Genetic Disorders: A Comprehensive Review.

Authors:  Altijana Hromić-Jahjefendić; Debmalya Barh; Cecília Horta Ramalho Pinto; Lucas Gabriel Rodrigues Gomes; Jéssica Lígia Picanço Machado; Oladapo Olawale Afolabi; Sandeep Tiwari; Alaa A A Aljabali; Murtaza M Tambuwala; Ángel Serrano-Aroca; Elrashdy M Redwan; Vladimir N Uversky; Kenneth Lundstrom
Journal:  Viruses       Date:  2022-04-27       Impact factor: 5.818

4.  Natural History and Molecular Characteristics of Korean Patients with Mucopolysaccharidosis Type III.

Authors:  Min-Sun Kim; Aram Yang; Eu-Seon Noh; Chiwoo Kim; Ga Young Bae; Han Hyuk Lim; Hyung-Doo Park; Sung Yoon Cho; Dong-Kyu Jin
Journal:  J Pers Med       Date:  2022-04-21

5.  From hypertransaminasemia to mucopolysaccharidosis IIIA.

Authors:  Paulina Krawiec; Elżbieta Pac-Kożuchowska; Beata Mełges; Agnieszka Mroczkowska-Juchkiewicz; Stanisław Skomra; Agnieszka Pawłowska-Kamieniak; Katarzyna Kominek
Journal:  Ital J Pediatr       Date:  2014-12-02       Impact factor: 2.638

6.  Progressive neurologic and somatic disease in a novel mouse model of human mucopolysaccharidosis type IIIC.

Authors:  Sara Marcó; Anna Pujol; Carles Roca; Sandra Motas; Albert Ribera; Miguel Garcia; Maria Molas; Pilar Villacampa; Cristian S Melia; Víctor Sánchez; Xavier Sánchez; Joan Bertolin; Jesús Ruberte; Virginia Haurigot; Fatima Bosch
Journal:  Dis Model Mech       Date:  2016-08-04       Impact factor: 5.758

7.  Recommendations on clinical trial design for treatment of Mucopolysaccharidosis Type III.

Authors:  Arunabha Ghosh; Elsa Shapiro; Stewart Rust; Kathleen Delaney; Samantha Parker; Adam J Shaywitz; Adelaida Morte; Gillian Bubb; Maureen Cleary; Tien Bo; Christine Lavery; Brian W Bigger; Simon A Jones
Journal:  Orphanet J Rare Dis       Date:  2017-06-26       Impact factor: 4.123

Review 8.  Sanfilippo syndrome: causes, consequences, and treatments.

Authors:  Anthony O Fedele
Journal:  Appl Clin Genet       Date:  2015-11-25

9.  Prediction of phenotypic severity in mucopolysaccharidosis type IIIA.

Authors:  Suzan J G Knottnerus; Stephanie C M Nijmeijer; Lodewijk IJlst; Heleen Te Brinke; Naomi van Vlies; Frits A Wijburg
Journal:  Ann Neurol       Date:  2017-10-26       Impact factor: 10.422

10.  Beneath the floor: re-analysis of neurodevelopmental outcomes in untreated Hurler syndrome.

Authors:  Elsa G Shapiro; Chester B Whitley; Julie B Eisengart
Journal:  Orphanet J Rare Dis       Date:  2018-05-11       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.